Scarica l'app Stockscreener
57.00
0.41%
0.23
Dopo l'orario di chiusura:
57.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Bristol Myers Squibb Co Borsa (BMY) Ultime notizie
Another pharma giant eyes Houston for $1B plant with hundreds of jobs possible - KHOU
Bristol Myers Squibb eyes Houston for $1B pharmaceutical plant - The Business Journals
Biopharma Collaboration: Bristol Myers Squibb Partners with Heng - GuruFocus
Bristol Myers Squibb partners with Hengrui Pharma to develop and test drugs early in China. - Pluang
Bristol Myers Squibb and Hengrui Forge $15.2 Billion Strategic Alliance, Reshaping China-Out Licensing Landscape - Oncodaily
Rx Rundown: Bristol Myers Squibb, Isomorphic Labs, Partner Therapeutics and more - Medical Marketing and Media
AustralianSuper Pty Ltd Decreases Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Strategic Advisers Fidelity Alternatives Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Sivia Capital Partners, LLC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Tempus AI, Bristol Myers Squibb Expand AI-Driven Clinical Trial Efforts - Benzinga
Tempus AI Stock (TEM) Opinions on Bristol Myers Squibb Partnership Expansion - Quiver Quantitative
Bristol-Myers Squibb Company stock (US0897961004): Dividend paid May 1 - AD HOC NEWS
Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience - The Joplin Globe
AI aims to reshape Bristol Myers’ cancer and Alzheimer’s drug trials - Stock Titan
Bristol-Myers Squibb stock (US1101221083): China deal worth up to $15.2B - AD HOC NEWS
Bristol Myers Squibb Company $BMY Shares Sold by Bank Julius Baer & Co. Ltd Zurich - MarketBeat
Hengrui Pharma And Bristol Myers Squibb Forge $15.2 Billion Strategic Alliance Across Oncology And Immunology - BioPharma APAC
MCDONALD PARTNERS LLC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
BMS, Hengrui Pharma Partner on 13 Programs in Up-to-$15.2B Collaboration - Genetic Engineering and Biotechnology News
Bristol-Myers Shuts Down Lawsuit Over Celgene Investor Rights - Bloomberg Law News
Global Colorectal Cancer Diagnostics and Therapeutics Market Anticipates Impressive Growth Trajectory at a CAGR of ~9% by 2034 | DelveInsight - GlobeNewswire Inc.
Cortisone Shots Market 2026 | Merck & Co, Pfizer, Bristol-Myers Squibb, Novartis, Pharmascience etc. - openPR.com
Bristol-Myers Squibb stock (US0897961004): $15.2B Hengrui Pharma drug partnership - AD HOC NEWS
Bernstein reiterates Bristol-Myers Squibb stock rating on China deal By Investing.com - Investing.com India
BMY Partners with Hengrui for $15.2 Billion Early-Stage Drug Dev - GuruFocus
Bernstein reiterates Bristol-Myers Squibb stock rating on China deal - Investing.com
BMY Technical Analysis | Trend, Signals & Chart Patterns | BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - ChartMill
Jiangsu Hengrui Pharmaceutical Signs $15.2 Billion Drug Deal With Bristol Myers Squibb Ahead of Trump’s China Visit - Daily Pioneer
M Stanley: HENGRUI PHARMA (01276.HK) Forms USD15.2B Strategic Partnership with Bristol-Myers Squibb Company (BMY.US) to Accelerate Globalization - AASTOCKS.com
Bristol Myers Squibb and Hengrui Pharma sign major licencing deal - FinanceAsia
NJ Court Not Sure Bristol-Myers Investor Pled Negligence - Law360
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Bristol-Myers Squibb and China’s Hengrui Pharma Forge Tie-Up - WSJ
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal - BioWorld News
BMS and Hengrui forge $15.2bn alliance for early-stage drugs - Pharmaceutical Technology
Bristol Myers Squibb (BMY) Valuation Check After Recent Share Weakness And Mixed 2024 Earnings - simplywall.st
Bristol Myers Squibb inks $15.2B drug deal with Hengrui - NJBIZ
Bristol Myers, Hengrui Pharma Team Up in Global Drug Research Pact That Could Top $15B - MedCity News
Bristol-Myers Squibb stock (US1101221083): Stock dips despite strong Q1 2026 earnings - AD HOC NEWS
BMO reiterates Bristol-Myers Squibb stock rating on Hengrui deal By Investing.com - Investing.com Nigeria
BMO reiterates Bristol-Myers Squibb stock rating on Hengrui deal - Investing.com UK
BMS and Hengrui Partner on 13 Oncology, Hematology, and Immunology Programs in Deal Worth Potentially $15.2 Billion - BioPharm International
Hengrui Pharma strikes $15.2 billion asset deal with BMS - The Pharma Letter
Hengrui Pharma and Bristol Myers Squibb Enter Strategic Collaboration to Advance Innovative Medicines - marketscreener.com
China's Hengrui, Bristol Myers Squibb sign collaboration, licensing deals - Reuters
Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion - BioPharma Dive
BMS-Hengrui Pact Highlights China’s Rising Role in Drug Development - PharmTech.com
Hengrui Pharma and Bristol Myers Squibb to advance innovative medicines across oncology, hematology, immunology - BioSpectrum Asia
BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal - BioSpace
China’s Hengrui Jumps After Inking USD15 Billion Innovative Drug Deal With BMS - Yicai Global
BMS, Hengrui strike $15.2B multi-asset pact - FirstWord Pharma
Hengrui & BMS Seal $15.2B Deal: China-US Pharma - Rediff MoneyWiz
Bristol Myers Squibb Expands Pipeline With Hengrui Multi Billion Drug Alliance - Yahoo Finance
Hengrui's Deal With Bristol Myers Squibb Should Ease Concerns Over Dealmaking Slowdown -- Market Talk - Moomoo
Bristol Myers Squibb Strikes $15.2 Billion Drug Development Deal With Hengrui Pharma - Benzinga
Bristol Myers joins Hengrui party in 13-asset deal worth up to $15.2B - Endpoints News
Hengrui, BMS Strike Huge $15.2bn Alliance For Bundle Of Preclinical Assets - Citeline News & Insights
Hengrui Pharma's Stock Jumps on Massive $1B Collaboration with Bristol-Myers - StockInvest.us
Bristol-Myers Inks Up to $15 Billion Licensing Deal With Hengrui - Bloomberg.com
1.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):